Your search for Warfarin returned 104 results

No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants

Morning or evening administration makes no difference on time outside target INR range.

Noninferiority not found compared with standard-intensity prophylaxis with hip or knee arthroplasty

Findings seen in warfarin-treated patients with history of international normalized ratio instability

Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.

Similar number of out-of-range next INR values for patients with, without extended testing interval

“Repackaging of warfarin sodium tablets into DAAs does not affect the chemical stability,” the authors wrote.

Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.

Overall, 808 and 789 patients in the genotype-guided and clinically-guided groups, respectively, completed the trial.

For patients with nonvalvular atrial fibrillation, warfarin is associated with a reduction in thromboembolism, although the correlation is attenuated after accounting for competing death events, according to a study published online Nov. 12 in the Journal of the American Geriatrics Society.